Ascendis Pharma (ASND) Misses Q4 EPS by 775c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR10.40), EUR7.75 worse than the analyst estimate of (EUR2.65). Revenue for the quarter came in at EUR51.17 million versus the consensus estimate of EUR19.55 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Morgan Stanley upgrades CDW on stronger AI-driven server demand